[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

GR3035460T3 - Methods for treating emesis and central nervous system disorders using optically pure (+) norcisapride - Google Patents

Methods for treating emesis and central nervous system disorders using optically pure (+) norcisapride

Info

Publication number
GR3035460T3
GR3035460T3 GR20010400294T GR20010400294T GR3035460T3 GR 3035460 T3 GR3035460 T3 GR 3035460T3 GR 20010400294 T GR20010400294 T GR 20010400294T GR 20010400294 T GR20010400294 T GR 20010400294T GR 3035460 T3 GR3035460 T3 GR 3035460T3
Authority
GR
Greece
Prior art keywords
norcisapride
nervous system
central nervous
optically pure
methods
Prior art date
Application number
GR20010400294T
Other languages
English (en)
Inventor
John R Mccullough
Thomas P Jerussi
Original Assignee
Sepracor Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sepracor Inc filed Critical Sepracor Inc
Publication of GR3035460T3 publication Critical patent/GR3035460T3/el

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4468—Non condensed piperidines, e.g. piperocaine having a nitrogen directly attached in position 4, e.g. clebopride, fentanyl
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Otolaryngology (AREA)
  • Nutrition Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
GR20010400294T 1996-07-19 2001-02-22 Methods for treating emesis and central nervous system disorders using optically pure (+) norcisapride GR3035460T3 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/684,753 US5739151A (en) 1996-07-19 1996-07-19 Method for treating emesis and central nervous system disorders using optically pure (+) norcisapride
PCT/US1997/011629 WO1998003173A1 (en) 1996-07-19 1997-07-02 Methods for treating emesis and central nervous system disorders using optically pure (+) norcisapride

Publications (1)

Publication Number Publication Date
GR3035460T3 true GR3035460T3 (en) 2001-05-31

Family

ID=24749413

Family Applications (1)

Application Number Title Priority Date Filing Date
GR20010400294T GR3035460T3 (en) 1996-07-19 2001-02-22 Methods for treating emesis and central nervous system disorders using optically pure (+) norcisapride

Country Status (25)

Country Link
US (3) US5739151A (el)
EP (1) EP0896539B1 (el)
JP (1) JP3097697B2 (el)
KR (4) KR100422492B1 (el)
CN (1) CN1215992A (el)
AT (1) ATE197762T1 (el)
AU (1) AU3592097A (el)
BG (1) BG63190B1 (el)
BR (1) BR9708287A (el)
CA (1) CA2245768C (el)
CZ (1) CZ293478B6 (el)
DE (1) DE69703617T2 (el)
DK (1) DK0896539T3 (el)
ES (1) ES2152687T3 (el)
GR (1) GR3035460T3 (el)
HU (1) HUP9904360A3 (el)
IL (1) IL125703A0 (el)
IS (1) IS4820A (el)
NO (2) NO317178B1 (el)
NZ (1) NZ331291A (el)
PL (1) PL189610B1 (el)
PT (1) PT896539E (el)
SK (1) SK282673B6 (el)
TR (1) TR199801816T2 (el)
WO (1) WO1998003173A1 (el)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5712293A (en) * 1995-06-07 1998-01-27 Sepracor, Inc. Methods for treating gastro-esophageal reflux disease and other disorders associated with the digestive tract using optically pure (-) norcisapride
US5739151A (en) * 1996-07-19 1998-04-14 Sepracor Inc. Method for treating emesis and central nervous system disorders using optically pure (+) norcisapride
US6147093A (en) * 1996-07-19 2000-11-14 Sepracor Inc. Methods for treating gastroesophageal reflux disease
WO1998016511A1 (en) * 1996-10-15 1998-04-23 Janssen Pharmaceutica N.V. Synthesis of cisapride
JP3529102B2 (ja) * 1997-07-11 2004-05-24 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノート シヤツプ ５−ｈｔ３および５−ｈｔ４介在性障害に有用な（＋）−ノルシサプリド
TR200103759T2 (tr) * 1998-06-15 2002-06-21 Sepracor Inc. Apne, bulimi ve başka bozuklukların tedavi edilmesi için optik açıdan saf (-) norsisapridin kullanımı
PT1089733E (pt) 1998-06-15 2005-08-31 Sepracor Inc Utilizacao de (+)-norcisaprida optixamente pura para tratamento da sindroma do colon irritavel
EP1468685A3 (en) * 1998-06-15 2004-12-15 Sepracor Inc. Use of optically pure (+)-norcisapride for treating apnea, bulimia and other disorders
EP1464333A3 (en) * 1998-06-15 2004-12-15 Sepracor Inc. Use of optically pure (-) norcisapride in the treatment of apnea, bulimia, and other disorders
KR100529659B1 (ko) * 1998-08-21 2005-11-21 노파르티스 아게 5-ｈｔ4 작동제 또는 길항제를 위한 신규한 경구 투여용제제
US6362202B1 (en) * 1999-03-02 2002-03-26 Sepracor Inc. Methods and compositions using (−) norcisapride in combination with proton pump inhibitors or H2 receptor antagonists
US6353005B1 (en) * 1999-03-02 2002-03-05 Sepracor, Inc. Method and compositions using (+) norcisapride in combination with proton pump inhibitors or H2 receptor antagonist
US6803387B1 (en) 1999-03-19 2004-10-12 Abbott Gmbh & Co. Kg Treatment of neuropathic pain or fibromyalgia
US20020013327A1 (en) * 2000-04-18 2002-01-31 Lee Andrew G. Compositions and methods for treating female sexual dysfunction
EP1321142A1 (en) * 2001-12-21 2003-06-25 Novartis AG Solid pharmaceutical composition for oral administration of Tegaserod
FR2854072B1 (fr) * 2003-04-23 2006-08-04 Centre Nat Rech Scient Vecteur pour administration par voie orale
PT2194053E (pt) * 2004-01-07 2013-07-08 Armetheon Inc Derivados de metoxipiperidina para utilização no tratamento de distúrbios gastrointestinais e do sistema nervoso central
US8138204B2 (en) * 2004-01-07 2012-03-20 Aryx Therapeutics, Inc. Stereoisomeric compounds and methods for the treatment of gastrointestinal and central nervous system disorders
US8524736B2 (en) 2004-01-07 2013-09-03 Armetheon, Inc. Stereoisomeric compounds and methods for the treatment of gastrointestinal and central nervous system disorders
US20090170899A1 (en) * 2004-09-14 2009-07-02 Guy Debonnel Stimulators of 5-HT4 receptors and uses thereof
WO2007028073A2 (en) * 2005-08-31 2007-03-08 Aryx Therapeutics, Inc. Synthetic methods and intermediates for stereoisomeric compounds useful for the treatment of gastrointestinal and central nervous system disorders
WO2007149929A1 (en) * 2006-06-23 2007-12-27 Aryx Therapeutics, Inc. Piperidine derivatives for the treatment of gastrointestinal and cns disorders
US20120208892A1 (en) 2009-10-16 2012-08-16 Epiomed Therapeutics, Inc. Emesis treatment
PL2678332T3 (pl) * 2011-02-25 2016-12-30 Pochodne diaminopirymidyny i sposoby ich wytwarzania

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5137896A (en) * 1981-10-01 1992-08-11 Janssen Pharmaceutica N.V. N-(3-hydroxy-4-piperidinyl)benzamide derivatives
US4962115A (en) * 1981-10-01 1990-10-09 Janssen Pharmaceutica N.V. Novel N-(3-hydroxy-4-piperidinyl)benzamide derivatives
US5057525A (en) * 1981-10-01 1991-10-15 Janssen Pharmaceutica N.V. Novel N-(3-hydroxy-4-piperidinyl) benzamide derivatives
CA1183847A (en) * 1981-10-01 1985-03-12 Georges Van Daele N-(3-hydroxy-4-piperidinyl)benzamide derivatives
US5114715A (en) * 1990-11-29 1992-05-19 Sepracor Inc. Methods of use and compositions of (s)-isoflurane and (s)-desflurane
US5114714A (en) * 1990-11-29 1992-05-19 Sepracor, Inc. Methods of use and compositions of (r)-isoflurane and (r)-desflurane
EP0649307A4 (en) * 1992-07-07 1996-06-26 Sepracor Inc METHOD FOR USING (-) - CISAPRIDE FOR TREATING GASTIC EYE ELEMENTS AND OTHER DISEASES.
EP1170010A3 (en) * 1992-07-07 2004-05-19 Sepracor Inc. Method of using (+) cisapride for the treatment of gastro-esophageal reflux disease and other disorders
WO1995001803A1 (en) * 1993-07-06 1995-01-19 Merck & Co., Inc. H2 antagonist-gastrointestinal motility agent combinations
US5712293A (en) * 1995-06-07 1998-01-27 Sepracor, Inc. Methods for treating gastro-esophageal reflux disease and other disorders associated with the digestive tract using optically pure (-) norcisapride
US5739151A (en) * 1996-07-19 1998-04-14 Sepracor Inc. Method for treating emesis and central nervous system disorders using optically pure (+) norcisapride

Also Published As

Publication number Publication date
CA2245768A1 (en) 1998-01-29
KR20040007505A (ko) 2004-01-24
NO983636L (no) 1998-10-19
BR9708287A (pt) 2000-01-18
DK0896539T3 (da) 2001-02-19
DE69703617D1 (de) 2001-01-04
EP0896539A1 (en) 1999-02-17
KR20000064524A (ko) 2000-11-06
US5739151A (en) 1998-04-14
CZ293478B6 (cs) 2004-05-12
WO1998003173A1 (en) 1998-01-29
ES2152687T3 (es) 2001-02-01
US6114356A (en) 2000-09-05
HUP9904360A3 (en) 2001-07-30
TR199801816T2 (xx) 2000-10-23
EP0896539B1 (en) 2000-11-29
US5877188A (en) 1999-03-02
JP3097697B2 (ja) 2000-10-10
IS4820A (is) 1998-08-10
IL125703A0 (en) 1999-04-11
ATE197762T1 (de) 2000-12-15
KR100399808B1 (ko) 2003-09-29
CA2245768C (en) 2003-09-30
PL189610B1 (pl) 2005-08-31
NO317178B1 (no) 2004-09-06
BG102757A (en) 1999-08-31
NO983636D0 (no) 1998-08-07
CN1215992A (zh) 1999-05-05
PT896539E (pt) 2001-05-31
DE69703617T2 (de) 2001-04-12
HUP9904360A2 (hu) 2000-05-28
PL335254A1 (en) 2000-04-10
JPH11510828A (ja) 1999-09-21
KR100422492B1 (ko) 2004-03-11
BG63190B1 (bg) 2001-06-29
AU3592097A (en) 1998-02-10
SK123998A3 (en) 1999-03-12
NO20041166L (no) 2004-03-19
SK282673B6 (sk) 2002-11-06
KR100533237B1 (ko) 2005-12-05
NZ331291A (en) 2000-06-23
KR100328731B1 (ko) 2002-10-19
CZ250898A3 (cs) 1999-04-14

Similar Documents

Publication Publication Date Title
GR3035460T3 (en) Methods for treating emesis and central nervous system disorders using optically pure (+) norcisapride
SG52320A1 (en) Novel (R)-5-carbamoyl-8-fluoro-3-N,N-disubstituted-amino-3,4-dihydro-2H-1-benzopyrans
EP0591434A4 (en) Method and compositions for treating emesis, nausea and other disorders using optically pure r(+) ondansetron
CA2180535A1 (en) A method for treatment of psoriasis, by omeprazole or related compounds
EE04491B1 (et) (+)-nortsisapriidi kasutamine
BG106065A (en) Method for the treatment of neurological or neuropsychiatric disorders
GB9212308D0 (en) Therapeutic compositions
GR3024592T3 (en) Process for preparing and resolving 2-phenyl-3-aminopiperidine
BG105218A (en) The use of optically pure (+) norcisapride for treating gastro-esophageal reflux disease
EP1049479A4 (en) ANALGESIC OBTAINED FROM SNAKE VENOM
IL142803A0 (en) Pharmaceutical compositions containing r-tofisopam
AU7777694A (en) Melatonin derivatives for use in treating desynchronization disorders
PL310950A1 (en) Novel imidazole quinoxalinones, method of obtaining them and their application
ZA976854B (en) Treatment of psychotic disorders.
AU4530796A (en) Treating disorders characterised by excessive cell proliferation with sclareolide
WO2004016604A3 (en) Azabicyclic compounds are central nervous system active agents
AU6919398A (en) Heterocyclic compounds and their preparation and use
GR3030635T3 (en) Use of substituted 6-amino-4h-pyrans
AU2002243310A1 (en) Isoindolyl and isoquinolinyl aroyl pyrrole compounds for the treatment of central nervous system disorders
UA10235A (uk) Спосіб корекції дезадаптаційних розладів організму
AU3978095A (en) Heterocyclic compounds and their preparation and use

Legal Events

Date Code Title Description
ML Lapse due to non-payment of fees